CRISPR/Cas9 technology introduced a lysine to aspartate substitution at amino acid 320 (D320K) which is predicted to abrogate VEGF164 binding to NRP1. (J:241872)
Legend:
cx: complex: > 1 genome feature ot: other: hemizygous, indeterminate,... (F): Female
(M): Male
N: normal phenotype
(#): related diseases count